GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Stratec SE (LTS:0RAR) » Definitions » Debt-to-EBITDA

Stratec SE (LTS:0RAR) Debt-to-EBITDA : 0.00 (As of Sep. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Stratec SE Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Stratec SE's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was €0.0 Mil. Stratec SE's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was €0.0 Mil. Stratec SE's annualized EBITDA for the quarter that ended in Sep. 2024 was €28.3 Mil. Stratec SE's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2024 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Stratec SE's Debt-to-EBITDA or its related term are showing as below:

LTS:0RAR' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.28   Med: 1.92   Max: 3.71
Current: 3.71

During the past 13 years, the highest Debt-to-EBITDA Ratio of Stratec SE was 3.71. The lowest was 1.28. And the median was 1.92.

LTS:0RAR's Debt-to-EBITDA is ranked worse than
76.1% of 431 companies
in the Medical Devices & Instruments industry
Industry Median: 1.54 vs LTS:0RAR: 3.71

Stratec SE Debt-to-EBITDA Historical Data

The historical data trend for Stratec SE's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stratec SE Debt-to-EBITDA Chart

Stratec SE Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.58 1.93 1.28 1.51 3.54

Stratec SE Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 2.55 - - -

Competitive Comparison of Stratec SE's Debt-to-EBITDA

For the Medical Devices subindustry, Stratec SE's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Stratec SE's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Stratec SE's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Stratec SE's Debt-to-EBITDA falls into.



Stratec SE Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Stratec SE's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(47.035 + 94.336) / 39.914
=3.54

Stratec SE's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / 28.316
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2024) EBITDA data.


Stratec SE  (LTS:0RAR) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Stratec SE Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Stratec SE's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Stratec SE Business Description

Traded in Other Exchanges
Address
Gewerbestrasse 37, Birkenfeld, RP, DEU, 75217
Stratec SE designs and manufactures automated analyzer systems for laboratory data management and solutions for molecular diagnostic sample preparation and stabilization. Its business segments are Instrumentation, Diatron and Smart Consumables. Its Instrumentation segment is engaged in designing and manufacturing automated analyzer systems for clinical diagnostics and biotechnology customers. The Diatron segment comprises the business with systems, system components, consumables, and tests in the low throughput hematology and clinical chemistry segment. Its Smart Consumables segment is engaged in developing and selling scientific materials, such as nucleic acid purification. The company generates maximum revenue from the Instrumentation segment.

Stratec SE Headlines

No Headlines